Article Details

ASX Health Stocks: Argenica's Phase 1 trial takes crucial step forward after drug safety confirmed

Retrieved on: 2022-11-18 09:10:14

Tags for this article:

Click the tags to see associated articles and topics

ASX Health Stocks: Argenica's Phase 1 trial takes crucial step forward after drug safety confirmed. View article details on hiswai:

Excerpt

Argenica Therapeutics (ASX:AGN) will progress to the third escalated dose cohort of Phase 1 after getting approval from safety committee.

Article found on: stockhead.com.au

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up